Immuneering (IMRX) Operating Expenses (2020 - 2026)

Immuneering's Operating Expenses history runs 7 years deep, the most recent figure standing at $15.3 million for Q1 2026.

• On a quarterly basis, Operating Expenses fell 0.97% year-over-year to $15.3 million in Q1 2026; TTM through Mar 2026 was $59.2 million, a 7.79% decrease from a year earlier, with the FY2025 full-year figure at $59.4 million, down 7.33% from the prior year.
• Operating Expenses advanced to $15.3 million in Q1 2026 per IMRX's latest filing, from $13.8 million in the prior quarter.
• Across five years, Operating Expenses topped out at $18.6 million in Q4 2024 and bottomed at $11.7 million in Q2 2022.
• The 5-year median for Operating Expenses is $14.8 million (2025), against an average of $14.7 million.
• Across the five-year window, Operating Expenses jumped 98.0% in 2022 and decreased 25.89% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $14.0 million in 2022, then rose by 16.56% to $16.3 million in 2023, then grew by 13.84% to $18.6 million in 2024, then fell by 25.89% to $13.8 million in 2025, then gained by 11.51% to $15.3 million in 2026.
• Per Business Quant, the three latest IMRX Operating Expenses figures stand at $15.3 million (Q1 2026), $13.8 million (Q4 2025), and $15.4 million (Q3 2025).